 Chemokine CXCL9
"Chemokine CXCL9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An INTEFERON-inducible CXC chemokine that is specific for the CXCR3 RECEPTOR.
| Descriptor ID |
D054370
|
| MeSH Number(s) |
D12.644.276.374.200.120.450 D12.776.467.374.200.120.450 D23.125.300.120.450 D23.469.200.120.450 D23.529.374.200.120.450
|
| Concept/Terms |
Chemokine CXCL9- Chemokine CXCL9
- CXCL9, Chemokine
- CXCL9 Chemokine
- Chemokine, CXCL9
- Monokine Induced by gamma Interferon Chemokine
- SCYB9 Chemokine
- Chemokine, SCYB9
- Small Inducible Cytokine B9
- Chemokine (C-X-C Motif) Ligand 9 Protein
- Mig Chemokine
- Chemokine, Mig
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL9".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL9".
This graph shows the total number of publications written about "Chemokine CXCL9" by people in this website by year, and whether "Chemokine CXCL9" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Chemokine CXCL9" by people in Profiles.
-
James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 04 01; 59(4):860-868.
-
Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
-
Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
-
Tortelli F, Pisano M, Briquez PS, Martino MM, Hubbell JA. Fibronectin binding modulates CXCL11 activity and facilitates wound healing. PLoS One. 2013; 8(10):e79610.
-
Guglani L, Gopal R, Rangel-Moreno J, Junecko BF, Lin Y, Berger T, Mak TW, Alcorn JF, Randall TD, Reinhart TA, Chan YR, Khader SA. Lipocalin 2 regulates inflammation during pulmonary mycobacterial infections. PLoS One. 2012; 7(11):e50052.
-
Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A. 2009 Nov 17; 106(46):19455-60.
-
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep; 117(1):83-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|